CA2903545C - Method of enhancing delivery of therapeutic compounds to the eye - Google Patents

Method of enhancing delivery of therapeutic compounds to the eye Download PDF

Info

Publication number
CA2903545C
CA2903545C CA2903545A CA2903545A CA2903545C CA 2903545 C CA2903545 C CA 2903545C CA 2903545 A CA2903545 A CA 2903545A CA 2903545 A CA2903545 A CA 2903545A CA 2903545 C CA2903545 C CA 2903545C
Authority
CA
Canada
Prior art keywords
plasmin
cell
retinal
eye
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2903545A
Other languages
English (en)
French (fr)
Other versions
CA2903545A1 (en
Inventor
Zhuo-Hua Pan
Elena Ivanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of CA2903545A1 publication Critical patent/CA2903545A1/en
Application granted granted Critical
Publication of CA2903545C publication Critical patent/CA2903545C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2903545A 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye Active CA2903545C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785015P 2013-03-14 2013-03-14
US61/785,015 2013-03-14
PCT/US2014/026224 WO2014160281A2 (en) 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye

Publications (2)

Publication Number Publication Date
CA2903545A1 CA2903545A1 (en) 2014-10-02
CA2903545C true CA2903545C (en) 2022-09-06

Family

ID=50687629

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903545A Active CA2903545C (en) 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye

Country Status (6)

Country Link
US (3) US9730888B2 (enExample)
EP (1) EP2968476B1 (enExample)
JP (3) JP6483083B2 (enExample)
AU (2) AU2014243925B2 (enExample)
CA (1) CA2903545C (enExample)
WO (1) WO2014160281A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
WO2018044912A1 (en) * 2016-08-29 2018-03-08 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
EP3508212B1 (en) * 2016-09-02 2025-10-22 Keio University Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
US11261236B2 (en) 2017-01-06 2022-03-01 Kyungpook National University Industry-Academic Cooperation Foundation Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof
WO2018181071A1 (ja) * 2017-03-28 2018-10-04 森永乳業株式会社 非コラーゲン性糖タンパク質分解用組成物
JP7707081B2 (ja) * 2019-05-17 2025-07-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 網膜細胞を標的とした最適化された遺伝子治療
WO2021049634A1 (ja) 2019-09-13 2021-03-18 株式会社レストアビジョン キメラロドプシンをコードする核酸コンストラクト
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
GB202002073D0 (en) * 2020-02-14 2020-04-01 Ucl Business Ltd Horizontal cells
WO2022059736A1 (ja) * 2020-09-17 2022-03-24 株式会社レストアビジョン 小胞体ストレスまたはオールトランスレチナールに関連する疾患、障害または症状を治療または予防するため、または網膜厚を保護し、または網膜厚の萎縮もしくは萎縮進行を抑制するための組成物。
JP2022184212A (ja) * 2021-05-31 2022-12-13 ユニ・チャーム株式会社 月経血を吸収するための吸収性物品
CN113355309B (zh) * 2021-08-10 2021-11-05 迈威(上海)生物科技股份有限公司 重组截短型人纤维蛋白溶酶制备工艺
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346262A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20080248021A1 (en) * 2005-06-30 2008-10-09 Ista Pharmaceuticals, Inc. Use of Hyaluronidase in Combination with Plasmin for the Induction of Posterior Vitreous Detachment
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US8470790B2 (en) * 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
WO2009067407A2 (en) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof
NZ597452A (en) * 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) * 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
EA201491643A1 (ru) 2012-03-05 2015-02-27 Уэйн Стейт Юниверсити Идентификация мутаций канал-опсина-2 (chop2) и способы применения

Also Published As

Publication number Publication date
EP2968476A2 (en) 2016-01-20
EP2968476B1 (en) 2021-05-05
AU2014243925A1 (en) 2015-10-08
US20160038409A1 (en) 2016-02-11
US9730888B2 (en) 2017-08-15
JP2021038240A (ja) 2021-03-11
JP2019055980A (ja) 2019-04-11
US20200268647A1 (en) 2020-08-27
JP6483083B2 (ja) 2019-03-13
AU2019201474A1 (en) 2019-03-28
WO2014160281A2 (en) 2014-10-02
US20180064640A1 (en) 2018-03-08
CA2903545A1 (en) 2014-10-02
AU2014243925B2 (en) 2018-12-06
HK1220625A1 (zh) 2017-05-12
JP2016519063A (ja) 2016-06-30
WO2014160281A3 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
US20200268647A1 (en) Method of enhancing delivery of therapeutic compounds to the eye
US20220040326A1 (en) Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
US9730981B2 (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
JP6240067B2 (ja) 光感受性キメラｇｐｃｒタンパク質
EP2822964B1 (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
WO2021204407A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
EP3892738A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
HK1220625B (en) A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
US20230338581A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
US20260048089A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
HK40004342A (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
HK1205744B (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251006

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428